V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 230001120 | 230000701 | 1.68 | 56.25 | Adjuvant (A) | 2014-07-28 | 2014-07-28 | Trastuzumab Subcutaneous | N | N | 230025074 | CAPECITABINE |
| 230001121 | 230000702 | 1.79 | 55.5 | Neo-adjuvant (N) | 2017-04-09 | 2017-04-09 | FLUOROURACIL + IRINOTECAN | 02 | N | 230025117 | CAPECITABINE + OXALIPLATIN |
| 230001122 | 230000702 | 1.9 | 127.2 | Palliative (P) | 2017-08-22 | 2017-09-17 | BCG Intravesical | N | N | 230025117 | CAPECITABINE + OXALIPLATIN |
| 230001123 | 230000702 | null | 76.8 | Not known (9) | null | 2014-05-12 | Capecitabine (21 day) + Irinotecan | N | null | 230025117 | CETUXIMAB |
| 230001124 | 230000705 | 1.6 | 68 | Palliative (P) | 2018-10-01 | 2018-10-19 | Sorafenib | N | N | 230025748 | CETUXIMAB + IRINOTECAN + MDG |
| 230001125 | 230000708 | 1.79 | 84 | Palliative (P) | 2016-11-11 | 2016-11-11 | Irinotecan 14day | 2 | N | 230025830 | OXALIPLATIN + MDG |
| 230001126 | 230000710 | 1.7 | 59.6 | Palliative (P) | 2019-02-14 | 2019-02-18 | AFLIBERCEPT + FU + IRINOTECAN | N | N | 230025957 | OXALIPLATIN + MDG |
| 230001127 | 230000710 | 1.8 | 73.5 | Palliative (P) | 2016-09-29 | 2016-10-20 | CARBOPLATIN + PACLITAXEL | null | N | 230025957 | CETUXIMAB |
| 230001128 | 230000712 | 1.57 | 0 | Adjuvant (A) | 2017-04-29 | 2017-04-29 | Capecitabine | 02 | N | 230026262 | IRINOTECAN + MDG |
| 230001129 | 230000714 | 1.66 | 127.2 | Adjuvant (A) | 2017-12-06 | 2017-12-07 | CAPECITABINE + OXALIPLATIN | N | N | 230026262 | RITUXIMAB |
| 230001130 | 230001573 | 1.9 | 92 | Palliative (P) | null | 2018-11-20 | Capecitabine + Oxaliplatin 21day | N | N | 230026662 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 230001132 | 230000717 | 1.63 | null | Adjuvant (A) | 2013-05-04 | 2013-05-16 | Trastuzumab 21 day maintenance | N | null | 230026715 | CAPECITABINE + OXALIPLATIN |
| 230001133 | 230001321 | 1.64 | null | Neo-adjuvant (N) | 2017-03-23 | 2017-03-24 | Fluorouracil 96hr infusion+R(4g/m2) | 02 | N | 230026771 | CAPECITABINE + RT |
| 230001134 | 230000718 | 1.61 | null | Palliative (P) | 2013-03-14 | 2013-03-14 | Cetuximab + FOLFIRI cycle 2 onwards | 2 | N | 230026784 | CETUXIMAB + IRINOTECAN + MDG |
| 230001135 | 230000720 | 1.75 | 54.4 | Not known (9) | 2014-12-29 | 2015-01-13 | Oxaliplatin + Modified de Gramont | N | N | 230026784 | CETUXIMAB + IRINOTECAN + MDG |
| 230001136 | 230001750 | 1.59 | 67.2 | Palliative (P) | 2017-01-30 | 2017-09-30 | Erlotinib | null | null | 230027145 | TRIFLURIDINE + TIPIRACIL |
| 230001137 | 230000721 | null | 53 | Neo-adjuvant (N) | null | 2016-10-03 | VANDETANIB | N | N | 230027511 | CAPECITABINE |
| 230001138 | 230000721 | 1.63 | 65.3 | Adjuvant (A) | 2016-05-30 | 2016-06-12 | Carboplatin + Pemetrexed | N | N | 230027511 | PEMBROLIZUMAB |
| 230001139 | 230000722 | null | 58.5 | Adjuvant (A) | 2018-03-02 | 2018-03-02 | Methotrexate intrathecal | 02 | N | 230027570 | IRINOTECAN + MDG |
| 230001140 | 230000722 | 1.8 | 76 | Palliative (P) | 2015-09-15 | 2015-10-10 | Capecitabine + Oxaliplatin 21day | N | N | 230027570 | CAPECITABINE + RT |
| 230001141 | 230000723 | 1.73 | 118 | Palliative (P) | 2016-10-12 | 2016-10-26 | FLUOROURACIL + IRINOTECAN | N | N | 230028000 | OXALIPLATIN + MDG |
| 230001142 | 230000723 | 1.57 | null | Adjuvant (A) | 2015-08-16 | 2015-09-08 | Trastuzumab Subcutaneous | N | N | 230028000 | OXALIPLATIN + MDG |
| 230001143 | 230000723 | 1.7 | 50.6 | Adjuvant (A) | 2016-03-24 | 2016-03-24 | Trastuzumab 21 day maintenance | N | N | 230028000 | IRINOTECAN + MDG |
| 230001144 | 230000724 | null | 69 | Adjuvant (A) | 2013-06-30 | 2013-07-09 | EVEROLIMUS | 02 | N | 230028556 | IRINOTECAN + MDG |
| 230001145 | 230000725 | null | 60.4 | Adjuvant (A) | 2016-01-19 | 2016-02-09 | Palbociclib | null | N | 230000010 | PACLITAXEL |
| 230001146 | 230000725 | 1.66 | null | Neo-adjuvant (N) | 2015-09-25 | 2015-10-03 | Capecitabine + Oxaliplatin 21day | 2 | N | 230000010 | EVEROLIMUS |
| 230001147 | 230000727 | 173 | 74.3 | Palliative (P) | 2014-01-19 | 2014-01-22 | Methotrexate intrathecal | N | N | 230000028 | CAPECITABINE |
| 230001148 | 230000729 | 1.67 | null | Adjuvant (A) | 2014-02-12 | 2014-02-20 | Oxaliplatin + Modified de Gramont | 02 | N | 230000042 | CAPECITABINE + OXALIPLATIN |
| 230001149 | 230000729 | 1.9 | 106.4 | Palliative (P) | 2018-01-28 | 2018-03-12 | LENVATINIB | 02 | N | 230000042 | AFLIBERCEPT + FU + IRINOTECAN |
| 230001150 | 230000729 | 1.84 | 59.6 | Adjuvant (A) | null | 2015-04-12 | Carboplatin AUC 2 - 5 | N | N | 230000042 | CAPECITABINE |
| 230001151 | 230000732 | 1.73 | 83.3 | Palliative (P) | 2015-09-03 | 2015-09-03 | Rituximab (Maintenance) | N | N | 230000436 | CAPECITABINE + OXALIPLATIN |
| 230001152 | 230000733 | 1.7 | 58 | Adjuvant (A) | 2015-07-11 | 2015-07-11 | Trial Unspecified | N | N | 230000550 | OXALIPLATIN + MDG |
| 230001153 | 230000734 | 1.53 | 69.9 | Palliative (P) | 2017-11-28 | 2017-11-29 | FLUOROURACIL + OXALIPLATIN | 02 | N | 230000597 | CAPECITABINE + OXALIPLATIN |
| 230001154 | 230000735 | 1.72 | 84 | Adjuvant (A) | null | 2016-11-19 | Carboplatin AUC 2 - 5 | N | N | 230000617 | IRINOTECAN + MDG |
| 230001155 | 230000736 | 1.63 | null | Palliative (P) | 2017-07-19 | 2017-07-23 | Carboplatin + Pemetrexed | 2 | N | 230000651 | IRINOTECAN + MDG |
| 230001156 | 230000737 | 1.66 | null | Palliative (P) | 2014-04-23 | 2014-05-17 | Folfirinox | N | N | 230000766 | AFLIBERCEPT + FU + IRINOTECAN |
| 230001157 | 230000738 | null | 54 | Not known (9) | 2018-09-23 | 2018-09-24 | Irinotecan + Modified De Gramont | null | N | 230000766 | CAPECITABINE + OXALIPLATIN |
| 230001158 | 230000739 | 1.64 | 69.1 | Palliative (P) | 2017-07-04 | 2017-07-04 | Sorafenib | N | N | 230000826 | CAPECITABINE + OXALIPLATIN |
| 230001159 | 230000740 | 1.61 | 62.8 | Curative (C) | null | 2016-04-23 | CHOP R | N | N | 230000830 | CISPLATIN + GEMCITABINE |
| 230001160 | 230000741 | 1.64 | 73.6 | Curative (C) | 2015-08-31 | 2015-09-12 | Cyclophosphamide High Dose | 02 | N | 230000889 | PEMETREXED |
| 230001161 | 230000743 | 1.5 | null | Palliative (P) | 2013-09-06 | 2013-09-13 | AFLIBERCEPT + FU + IRINOTECAN | 2 | N | 230000898 | OXALIPLATIN + MDG |
| 230001162 | 230000746 | 1.73 | 90.6 | Adjuvant (A) | 2018-05-08 | 2018-05-15 | CABOZANTINIB | null | N | 230000916 | CETUXIMAB |
| 230001163 | 230000747 | null | 68.4 | Palliative (P) | 2017-07-12 | 2017-07-12 | AXITINIB | 2 | N | 230000976 | CETUXIMAB + MDG |
| 230001164 | 230000749 | 1.78 | 99 | Adjuvant (A) | 2016-04-22 | 2016-04-22 | CAPECITABINE + OXALIPLATIN | 02 | N | 230000981 | CETUXIMAB + IRINOTECAN + MDG |
| 230001165 | 230000753 | 1.73 | 128 | Palliative (P) | 2017-05-14 | 2017-08-17 | Ipilimumab | N | N | 230001034 | CAPECITABINE + OXALIPLATIN |
| 230001166 | 230001337 | 1.84 | 90.8 | Palliative (P) | 2015-10-13 | 2015-10-13 | BEVACIZUMAB + FLUOROURACIL | 02 | N | 230001198 | IRINOTECAN + MDG |
| 230001167 | 230000755 | 1.75 | 72.8 | null | 2014-07-21 | 2014-10-11 | MPT | 02 | N | 230001226 | TRIFLURIDINE + TIPIRACIL |
| 230001168 | 230000756 | 1.56 | null | Palliative (P) | 2018-12-03 | 2018-12-03 | Trastuzumab 21 day maintenance | 02 | N | 230001261 | CAPECITABINE |
| 230001169 | 230000758 | 1.62 | 53 | Palliative (P) | 2015-12-24 | 2016-01-10 | AFLIBERCEPT + FU + IRINOTECAN | N | N | 230001387 | IRINOTECAN |
| 230001170 | 230000760 | 1.59 | -1 | Palliative (P) | 2016-12-09 | 2016-12-31 | Trastuzumab 21 day maintenance | N | Y | 230001484 | EVEROLIMUS |